Chengdu Kanghong Pharmaceuticals Group Co Ltd Total Assets
Chengdu Kanghong Pharmaceuticals Group Co Ltd total assets. Based on the latest financial reports, Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773) holds total assets worth CN¥9.94 Billion CNY (≈ $1.45 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Chengdu Kanghong Pharmaceuticals Group C worth for the company's overall valuation and market capitalisation.
Total Assets of Chengdu Kanghong Pharmaceuticals Group Co Ltd (2009–2025)
Total assets of Chengdu Kanghong Pharmaceuticals Group Co Ltd from 2009 to 2025. This chart illustrates how Chengdu Kanghong Pharmaceuticals Group Co Ltd's total assets have evolved over time, based on quarterly financial data. See 002773 stock price for real-time trading data and today's change.
Chengdu Kanghong Pharmaceuticals Group Co Ltd - Asset Composition Analysis
Chengdu Kanghong Pharmaceuticals Group Co Ltd Total Assets Breakdown (December 2025)
Chengdu Kanghong Pharmaceuticals Group Co Ltd total assets breakdown as of December 2025. Chengdu Kanghong Pharmaceuticals Group Co Ltd's total assets of CN¥9.94 Billion consist of 71.4% current assets and 28.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 64.9% |
| Accounts Receivable | CN¥189.10 Million | 1.9% |
| Inventory | CN¥407.05 Million | 4.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥413.59 Million | 4.2% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2009–2025)
This chart illustrates how Chengdu Kanghong Pharmaceuticals Group Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 002773 net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Chengdu Kanghong Pharmaceuticals Group Co Ltd's current assets represent 71.4% of total assets in 2025, an increase from 47.6% in 2009.
- Cash Position: Cash and equivalents constituted 64.9% of total assets in 2025, up from 22.6% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 13.0% in 2009.
- Asset Diversification: The largest asset category is intangible assets at 4.2% of total assets.
Chengdu Kanghong Pharmaceuticals Group Co Ltd Competitors by Total Assets
Key competitors of Chengdu Kanghong Pharmaceuticals Group Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Sandoz Group AG
SW:SDZ
|
Switzerland | CHF22.86 Billion |
|
H Lundbeck A/S
CO:HLUN-B
|
Denmark | Dkr54.01 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Viyash Scientific Limited
NSE:SEQUENT
|
India | Rs17.26 Billion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥5.11 Billion |
Chengdu Kanghong Pharmaceuticals Group Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.03 | 10.26 | 6.05 |
| Quick Ratio | 9.47 | 9.68 | 5.63 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥6.44 Billion | CN¥5.99 Billion | CN¥3.21 Billion |
Chengdu Kanghong Pharmaceuticals Group Co Ltd - Advanced Valuation Insights
This section examines the relationship between Chengdu Kanghong Pharmaceuticals Group Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.90 |
| Latest Market Cap to Assets Ratio | 0.28 |
| Asset Growth Rate (YoY) | 6.2% |
| Total Assets | CN¥9.92 Billion |
| Market Capitalization | $2.73 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Chengdu Kanghong Pharmaceuticals Group Co Ltd's assets below their book value (0.28x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Chengdu Kanghong Pharmaceuticals Group Co Ltd's assets grew by 6.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Chengdu Kanghong Pharmaceuticals Group Co Ltd (2009–2025)
The table below shows the annual total assets of Chengdu Kanghong Pharmaceuticals Group Co Ltd from 2009 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥9.92 Billion ≈ $1.45 Billion |
+6.19% |
| 2024-12-31 | CN¥9.34 Billion ≈ $1.37 Billion |
+9.52% |
| 2023-12-31 | CN¥8.53 Billion ≈ $1.25 Billion |
+10.48% |
| 2022-12-31 | CN¥7.72 Billion ≈ $1.13 Billion |
+10.99% |
| 2021-12-31 | CN¥6.96 Billion ≈ $1.02 Billion |
-0.67% |
| 2020-12-31 | CN¥7.00 Billion ≈ $1.02 Billion |
+20.18% |
| 2019-12-31 | CN¥5.83 Billion ≈ $852.68 Million |
+12.17% |
| 2018-12-31 | CN¥5.19 Billion ≈ $760.17 Million |
+13.27% |
| 2017-12-31 | CN¥4.59 Billion ≈ $671.10 Million |
+22.03% |
| 2016-12-31 | CN¥3.76 Billion ≈ $549.94 Million |
+29.54% |
| 2015-12-31 | CN¥2.90 Billion ≈ $424.54 Million |
+49.48% |
| 2014-12-31 | CN¥1.94 Billion ≈ $284.01 Million |
+14.51% |
| 2013-12-31 | CN¥1.69 Billion ≈ $248.03 Million |
+14.41% |
| 2012-12-31 | CN¥1.48 Billion ≈ $216.80 Million |
+14.32% |
| 2011-12-31 | CN¥1.30 Billion ≈ $189.64 Million |
+30.77% |
| 2010-12-31 | CN¥991.06 Million ≈ $145.02 Million |
+20.35% |
| 2009-12-31 | CN¥823.48 Million ≈ $120.50 Million |
-- |
About Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chengdu Kanghong Pharmaceutical Group Co., Ltd engages in the research, development, manufacture, and sale of pharmaceuticals and medical devices in China. It develops medicines for ophthalmic, neuropsychiatric, and others. The company was founded in 1996 and is headquartered in Chengdu, China.